Mereo BioPharma Group plc

Equities

MREO

US5894921072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.74 ^USD	-2.49%		+3.79%	+18.61%

Apr. 26	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT
Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Mereo BioPharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2023

March 27, 2024 at 05:20 pm EDT

Mereo BioPharma Group plc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 10 million. Net loss was USD 29.47 million compared to USD 42.22 million a year ago.

Basic loss per share from continuing operations was USD 0.2 compared to USD 0.35 a year ago.

Latest news about Mereo BioPharma Group plc

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	Mar. 28	MT
Needham Adjusts Price Target on Mereo BioPharma to $6 From $5, Keeps Buy Rating	Mar. 28	MT
Mereo BioPharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading	Mar. 22	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	Mar. 15	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Feb. 29	MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%	Feb. 23	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading	Feb. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week Higher	Feb. 02	MT
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading	Feb. 01	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6%	Jan. 26	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Thursday Trading	Jan. 25	MT
European Equities Traded in the US as American Depositary Receipts Open Trading Week Modestly Higher Monday	Jan. 22	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Jan. 18	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Jan. 17	MT
European Equities Traded in the US as American Depositary Receipts Trade Sharply Lower in Tuesday Trading	Jan. 16	MT
European Equities Traded in the US as American Depositary Receipts Edge Higher Friday	Jan. 12	MT

Chart Mereo BioPharma Group plc

Duration

Period

More charts

Company Profile

Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

Sector

Biotechnology & Medical Research

Calendar

2024-09-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mereo BioPharma Group plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.2 GBP

Average target price

4.566 GBP

Spread / Average Target

+107.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEREO BIOPHARMA GROUP PLC	+18.61%	384M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs